El Hage Chehade Hiba, Wazir Umar, Mokbel Kinan, Kasem Abdul, Mokbel Kefah
The London Breast Institute, The Princess Grace Hospital, London, UK.
The London Breast Institute, The Princess Grace Hospital, London, UK.
Am J Surg. 2018 Jan;215(1):171-178. doi: 10.1016/j.amjsurg.2017.05.006. Epub 2017 Jun 3.
Decision-making regarding adjuvant chemotherapy has been based on clinical and pathological features. However, such decisions are seldom consistent. Web-based predictive models have been developed using data from cancer registries to help determine the need for adjuvant therapy. More recently, with the recognition of the heterogenous nature of breast cancer, genomic assays have been developed to aid in the therapeutic decision-making.
We have carried out a comprehensive literature review regarding online prognostication tools and genomic assays to assess whether online tools could be used as valid alternatives to genomic profiling in decision-making regarding adjuvant therapy in early breast cancer.
Breast cancer has been recently recognized as a heterogenous disease based on variations in molecular characteristics. Online tools are valuable in guiding adjuvant treatment, especially in resource constrained countries. However, in the era of personalized therapy, molecular profiling appears to be superior in predicting clinical outcome and guiding therapy.
关于辅助化疗的决策一直基于临床和病理特征。然而，此类决策很少一致。基于网络的预测模型已利用癌症登记处的数据开发出来，以帮助确定辅助治疗的必要性。最近，随着对乳腺癌异质性本质的认识，基因组检测已被开发出来以辅助治疗决策。
我们对在线预后工具和基因组检测进行了全面的文献综述，以评估在线工具是否可作为早期乳腺癌辅助治疗决策中基因组分析的有效替代方法。
基于分子特征的差异，乳腺癌最近被认为是一种异质性疾病。在线工具在指导辅助治疗方面很有价值，尤其是在资源有限的国家。然而，在个性化治疗时代，分子分析在预测临床结果和指导治疗方面似乎更具优势。
